ANI Pharmaceuticals提交8-K披露二季度业绩发布与投资者材料

0001023024
FALSE
0001023024
2026-08-07
2026-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
August 7, 2026
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-31812
58-2301143
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
104 Carnegie Center Drive, Suite 300
Princeton
,
New Jersey
08540
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
609
)
759-1810
Not Applicable
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock
ANIP
Nasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 2.02
Results of Operations and Financial Condition
On August 7, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results f
or the second quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.*
Item 7.01
Regulation FD Disclosure
On August 7, 2026, the Company published an updated investor presentation to the investor relations section of its website. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. A copy of the investor presentation is attached as Exhibit 99.2 hereto and incorporated herein by reference.*
Item 9.01
Exhibits
(d)
Exhibits
Exhibit
No.
Description
99.1
Press Release of the Company, dated
August 7
, 2026
99.2
Investor Presentation, dated August
2026
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
*
The information in Item 2.02 and Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 7, 2026
ANI PHARMACEUTICALS, INC.
By:
/s/ Stephen P. Carey
Name:
Stephen P. Carey
Title:
Senior Vice President Finance and Chief Financial Officer